Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients

Journal of Clinical Psychopharmacology

Volumn 17, Issue 6, 1997, Pages 472-477

  Perry, Paul J ^a,b   Sanger, Todd ^c   Beasley, Charles ^c  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OLANZAPINE; PLACEBO;

ACUTE DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; FEMALE; HUMANS; MALE; MIDDLE AGED; PIRENZEPINE; SCHIZOPHRENIA;

EID: 0031402808     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199712000-00006     Document Type: Article

References (23)

1. Beasley CM, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S, The Olanzapine HGAD Study Group. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-23.
2. Beasley CM, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: results of a double-blind fixed-dose olanzapine trial. Psychopharmacology 1996;124:159-67.
3. Tye NC, Moore NA, Rees G, Sanger G, Calligaro DO, Beasley CM. Preclinical pharmacology of olanzapine: a novel "atypical" antipsychotic agent. Second International Conference on Schizophrenia, Vancouver, British Columbia, July 1992.
4. Moore NA, Tye NC, Axton MS, Risius FC. The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J Pharmacol Exp Ther 1992;262:545-61.
5. Moore NA, Calligaro DO, Wong TD, Bymaster F, Tye NC. The pharmacology of olanzapine and other new antipsychotic agents. Curr Opin Invest Drugs 1993;2:281-93.
6. Wong DT, Moore NA, Calligaro O, Bymater FP, Seeman P. The preclinical pharmacology of olanzapine, a novel antipsychotic. Ninth World Congress of Psychiatry, Rio de Janeiro, Brazil, June 1993.
7. Perry PJ, Smith DA. Antipsychotic plasma concentrations: an estimate of their sensitivity and specificity as predictors of response. In: Marder S, Davis J, eds. The clinical use of antipsychotic plasma levels. Washington, DC: American Psychiatric Press, 1992:113-136.
8. Perry PJ, Miller DD, Arndt SV, Cadoret R. Clozapine and norclozapine plasma concentrations and clinical response in treatment-refractory schizophrenics. Am J Psychiatry 1991;148:231-5.
9. Perry PJ, Miller DD. The clinical utility of clozapine plasma concentrations. In: Marder S, Davis J, eds. The clinical use of antipsychotic plasma levels. Washington, DC: American Psychiatric Press, 1992:85-100.
10. Hasegawa M, Gutierrez-Esteinou R, Way L, Meltzer HY. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J Clin Psychopharmacol 1993;13:383-90.
11. Potkin SG, Bera R, Gulasekaram B, Costa J, Hayes S, Jin Y, Richmond G, Carreon D, Sitanggan K, Gerber B. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry 1994;55[suppl B]:133-6.
12. Kronig MH, Munne RA, Szymanski S, Safferman AZ, Pollack S, Cooper T, Kane JM, Lieberman JA. Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry 1995;152:179-82.
13. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96.
14. Overall JE. The Brief Psychiatric Rating Scale in psychopharmacology research. In: Pichot P, ed. Psychological measurements in psychopharmacology: modern problems in pharmacopsychiatry, vol. 7. Basel: Karger, 1974:67-78.
15. Kay SR. Positive and negative syndromes in schizophrenia: assessment and research. New York: Brunner/Mazel, 1991.
16. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;212[suppl]:11-9.
17. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-6.
18. Guy W. ECDEU assessment manual for psychopharmacology. Washington, DC: US Government Printing Office, 1976.
19. Catlow JT, Barton RD, Clemens M, Gillespie TA, Goodwin M, Swanson SP. Analysis of olanzapine in human plasma utilizing reversed-phase high performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Appl 1995;668: 85-90.
20. Mossman D, Somoza E. ROC curves, test accuracy, and the description of diagnostic tests. J Neuropsychiatry Clin Neurosci 1991;3:330-3.
21. Owen RR, Beake BJ, Marby D, Dessain DC, Cole JO. Response to clozapine in chronic psychotic patients. Psychopharmacol Bull 1989;25:253-6.
22. Meltzer HY. Duration of a clozapine trial in neuroleptic-resistant schizophrenia [letter]. Arch Gen Psychiatry 1989;46:672.
23. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13: 25-40.